Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Aravive, Inc.
  6. Summary
    ARAV   US03890D1081

ARAVIVE, INC.

(ARAV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
3.62(c) 3.76(c) 3.79(c) 3.83(c) 3.68(c) Last
50 167 20 500 41 124 61 289 37 545 Volume
+1.40% +3.87% +0.80% +1.06% -3.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,38 M - -
Net income 2021 -35,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,08x
Yield 2021 -
Sales 2022 6,13 M - -
Net income 2022 -50,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,69x
Yield 2022 -
Capitalization 76,2 M 76,2 M -
Capi. / Sales 2021 10,3x
Capi. / Sales 2022 12,4x
Nbr of Employees 17
Free-Float 62,0%
More Financials
Company
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing transformative treatments designed to halt the progression of life-threatening diseases. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. The Company is... 
More about the company
Ratings of Aravive, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ARAVIVE, INC.
10/01ARAVIVE : to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear ..
AQ
10/01Aravive, Inc. to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in..
CI
09/16Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare ..
GL
09/10ARAVIVE, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements ..
AQ
09/01Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investmen..
GL
08/09ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
08/09ARAVIVE : Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Tr..
AQ
08/09Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for t..
CI
08/06ARAVIVE : Piper Sandler Adjusts Aravive's Price Target to $18 From $20, Maintains Overweig..
MT
08/05ARAVIVE : Q2 Earnings Snapshot
AQ
08/05ARAVIVE : Earnings Flash (ARAV) ARAVIVE Posts Q2 Revenue $3.8M
MT
08/05ARAVIVE : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
08/05ARAVIVE, INC. : Results of Operations and Financial Condition, Financial Statements and Ex..
AQ
08/05Aravive, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/05ARAVIVE : Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
AQ
More news
News in other languages on ARAVIVE, INC.

- No features available -

More news
Analyst Recommendations on ARAVIVE, INC.
More recommendations
Chart ARAVIVE, INC.
Duration : Period :
Aravive, Inc. Technical Analysis Chart | ARAV | US03890D1081 | MarketScreener
Technical analysis trends ARAVIVE, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,68 $
Average target price 22,00 $
Spread / Average Target 498%
EPS Revisions
Managers and Directors
Gail Frances McIntyre President, Chief Executive Officer & Director
Vinay Shah Chief Financial Officer
Fredric N. Eshelman Chairman
Reshma Rangwala Chief Medical Officer
Amy Franke Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ARAVIVE, INC.-34.75%76
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156